Connect Biopharma's headline puts two qualifiers ahead of the result: "Positive Preliminary Topline Data." The trial is a global Phase 2 of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. $CNTB is +77.42% before the bell.
Topline is the summary page. Preliminary means the full dataset isn't out yet. Add-on means the drug was given on top of existing care. The number that matters is how much it helped beyond that care, and the headline doesn't print it.
CNTB's own record is short. It has 10 prior sessions that opened with a gap-up of 5% or more. In 7 of them (70%), the stock closed below that session's open. The median open-to-close was -6.79%. Ten sessions is a small sample, and it describes those sessions, not this one.
Yesterday we did the same close reading of a uniQure data headline. That stock opened 23.85 and closed 24.51, above its open. The reading was still worth doing, and the close was the part it couldn't tell us.
Same noun, opposite tape. #RFL announced topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick disease type C, and it is -31.53% premarket. Its headline carries no adjective at all. "Positive" is a word a company chooses to print. The full readout is what has to back it up.